✦ Patient Information

Your Medications

Detailed prescribing information for the two GLP-1 receptor agonist medications used in the LSJ Rejuvenate programme — Semaglutide (Wegovy®) and Tirzepatide (Mounjaro®). This page is for informational purposes only. Always follow the instructions given by your Nurse Consultant.

Prescription-only medicines

Clinically supervised treatment

Once-weekly injection

Important: This page provides general prescribing information for educational purposes. It does not replace the Patient Information Leaflet (PIL) supplied with your medication or the clinical advice of your Nurse Consultant. Always read the PIL included in your medication pack and contact your Nurse Consultant if you have any concerns.

What is Semaglutide (Wegovy®)?

Semaglutide (brand name Wegovy®, manufactured by Novo Nordisk) is a GLP-1 receptor agonist — a class of medicine that mimics the action of glucagon-like peptide-1, a hormone naturally produced in the gut after eating. It is licensed in the UK for chronic weight management in adults with a BMI of ≥30 kg/m², or ≥27 kg/m² with at least one weight-related health condition.

Semaglutide works primarily by acting on receptors in the brain (hypothalamus) to reduce appetite and increase feelings of fullness. It also slows gastric emptying, meaning food stays in the stomach longer, which further reduces hunger. It is administered as a once-weekly subcutaneous (under the skin) injection using a pre-filled FlexTouch® pen.

Active ingredient

Semaglutide 2.4 mg (maintenance)

Manufacturer

Novo Nordisk Limited

Administration

Once-weekly subcutaneous injection

Pen device

Wegovy® FlexTouch® pre-filled pen

Injection sites

Abdomen, thigh, or upper arm

UK licence

MHRA-approved for weight management

Dose Titration Schedule

Semaglutide is started at a low dose and gradually increased (titrated) over approximately 16 weeks to reach the maintenance dose. This gradual escalation is essential to minimise side effects, particularly nausea. Your Nurse Consultant will supervise your titration and may adjust the schedule based on your individual response and tolerability.

Phase	Dose	Duration	Notes
Starting dose	0.25 mg	Weeks 1–4	Initiation dose only — not a therapeutic dose. Allows body to adjust.
Escalation 1	0.5 mg	Weeks 5–8	First therapeutic dose. Most patients begin to notice appetite suppression.
Escalation 2	1.0 mg	Weeks 9–12	Increased if 0.5 mg tolerated well. Dose may be maintained if sufficient response.
Escalation 3	1.7 mg	Weeks 13–16	Optional escalation based on clinical response and tolerability.
Maintenance	2.4 mg	Week 17 onwards	Maximum approved maintenance dose. Dose may be reduced if not tolerated.

Note: Your Nurse Consultant may recommend staying at a lower dose for longer if side effects are significant, or if you are achieving good results at a lower dose. The goal is the lowest effective dose, not necessarily the maximum.

Contraindications — Who Should Not Use Wegovy®

Semaglutide is not suitable for everyone. Your Nurse Consultant will assess your full medical history before prescribing. Do not use Wegovy® if any of the following apply:

You are allergic to semaglutide or any of the other ingredients in Wegovy®

You or any member of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC)

You have a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

You are pregnant or planning to become pregnant (effective contraception must be used during treatment)

You are breastfeeding

You have a personal or family history of pancreatitis

You have severe gastrointestinal disease (e.g. gastroparesis)

You are under 18 years of age

Use with caution if you have a history of diabetic retinopathy, kidney problems, depression or suicidal ideation, or if you are taking other medications that affect blood sugar. Always disclose your full medical history and all medications to your Nurse Consultant.

Possible Side Effects

Like all medicines, Wegovy® can cause side effects, although not everyone gets them. Most side effects are mild to moderate and occur mainly during the dose escalation phase. They typically improve as your body adjusts to the medication.

Very common (≥1 in 10)

Nausea
Diarrhoea
Vomiting
Constipation
Abdominal pain

Common (1 in 10 to 1 in 100)

Headache
Fatigue
Dizziness
Gastroesophageal reflux (heartburn)
Belching
Flatulence
Injection site reactions
Hair loss (telogen effluvium)

Uncommon (1 in 100 to 1 in 1,000)

Gallstones
Increased heart rate
Acute pancreatitis (seek urgent medical attention)
Allergic reactions

Serious — seek urgent help

Severe abdominal pain (possible pancreatitis)
Signs of allergic reaction (rash, swelling, difficulty breathing)
Changes in vision (diabetic retinopathy)
Suicidal thoughts or worsening depression

Storage Instructions

Before first use

Store in a refrigerator (2°C–8°C). Do not freeze. Keep away from the cooling element.

After first use

Can be stored at room temperature (below 30°C) or in the refrigerator for up to 6 weeks.

Light protection

Keep the pen cap on when not in use. Store away from direct sunlight.

Disposal

Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use.

Official Patient Information Leaflet (PIL)

The official UK Patient Information Leaflet for Wegovy® is published by the Electronic Medicines Compendium (emc) and is updated whenever the product information changes. It contains the complete, authoritative prescribing information approved by the MHRA.

View Wegovy® PIL on emc Download PIL as PDF

Source: Electronic Medicines Compendium (emc) — medicines.org.uk. Last updated January 2026. PIL provided by Novo Nordisk Limited.

Injection Guidance

General guidance for administering your weekly injection safely. Always read the Instructions for Use in your medication pack.

Prepare

Remove pen from refrigerator 30 minutes before use. Check the expiry date and that the solution is clear and colourless. Wash your hands thoroughly.

Choose site

Inject into the abdomen (at least 5 cm from navel), upper thigh, or upper arm. Rotate injection sites each week to prevent skin reactions.

Inject

Clean the skin with an alcohol swab and allow to dry. Insert the needle at a 90° angle. Press and hold the injection button until the dose counter shows 0.

After injection

Remove the needle and apply gentle pressure. Do not rub the injection site. Replace the pen cap. Dispose of used needles in a sharps bin immediately.

Sharps disposal: Used needles must be disposed of in a sharps bin. Never dispose of needles in household waste. Your Nurse Consultant can advise on obtaining and disposing of a sharps bin in your area.

Injection Tutorial Videos

Step-by-step video guides for using your injection pen correctly.

How to Use the Wegovy® FlexTouch® Pen

Step-by-step guide from Boots Online Doctor

This video covers preparing the pen, choosing an injection site, administering the dose, and safe disposal. Always read the Instructions for Use included in your Wegovy® pack.

How to Use the Mounjaro® KwikPen®

Step-by-step guide — Mounjaro KwikPen tutorial

This video demonstrates the full injection process for the Mounjaro KwikPen, including dose dialling, injection technique, and aftercare. Always read the Instructions for Use included in your Mounjaro® pack.

These videos are provided for educational purposes only. They are not produced by LSJ Rejuvenate. Always follow the specific instructions provided with your medication pack and the guidance of your Nurse Consultant.

Medication FAQs

Medical Disclaimer: The information on this page is provided for general educational purposes only and does not constitute medical advice. It is not a substitute for the Patient Information Leaflet supplied with your medication, or the clinical advice of your Nurse Consultant. Always read the PIL included in your medication pack. If you have any concerns about your medication, contact your Nurse Consultant or call 111 in an emergency. Report side effects to the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.